543389

- Sigachi Industries Limited will hold an Extra-Ordinary General Meeting (EGM) on September 15, 2026, at 11:00 AM via Video Conference/OAVM. The e-voting cut-off date is September 08, 2026. - The EGM will consider increasing the Authorized Share Capital from ₹43,00,00,000 to ₹60,00,00,000. - It will also consider issuing up to 11,00,00,000 (11 Crore) Convertible Warrants at ₹26.40 per warrant on a preferential basis, aggregating to ₹290,40,00,000. - The funds raised will be utilized for: Acquisition/Expansion of Active Pharmaceutical Ingredients (API) and Excipients (₹190.40 Crores), Working Capital (₹60.00 Crores), and General Corporate Purposes (₹40.00 Crores).

- Sigachi Industries Limited filed a correction to the outcome of its Board Meeting held on August 22, 2026. - The correction pertains to a typographical error where the proposed allottee 'K Neelima' was mistakenly mentioned as 'Anil Kondoth' at Sl. No. 34.

- Board approved increasing authorized share capital from ₹43Cr to ₹60Cr. - Approved preferential allotment of up to 11 crore convertible warrants at ₹26.40 each, raising ~₹290.4Cr. - An EGM is scheduled for September 15, 2026, to approve these proposals. - M/s. PRSV & Co. LLP resigned as Internal Auditors; M/s. RSM Astute Consulting Private Limited appointed as new Internal Auditors for FY 2026-27.

- Board approved increasing authorized share capital and a preferential issue of 11 crore convertible warrants at ₹26.40 each (approx. ₹290.4 Cr), subject to EGM approval on Sept 15, 2026. - M/s. PRSV & Co. LLP resigned as Internal Auditors and M/s. RSM Astute Consulting Private Limited was appointed.

- FY27 revenue guidance of INR650-675 crores. - FY27 EBITDA margin guidance of 18%. - Q1 FY27 MCC average realization increased to INR241.36/kg from INR216/kg in Q4. - Dahej-2 MCC capacity expansion (12,000 MT/annum) to reach a total of 30,000 MT/annum, targeted for commissioning by Q2 FY28. - New Croscarmellose Sodium (CCS) facility (1,800 MT) is advancing, with expected margins of 25%+ and an export focus. - Launched HiCel SMCC Nutra, a new product for nutraceutical formulations. - Expects API revenue to achieve INR100-110 crores or more for FY27. - FY27 capex >INR100 crores, and FY28 capex of INR150-200 crores, to be funded via internal accruals, borrowings, or preferential equity. - Insurance claim of INR16.5 crores for a past incident is expected to be settled by September. - Aims to reduce receivables from current 93-94 days to 90 days by year-end and then to 75-80 days.

- Sigachi Industries Limited Board Meeting scheduled for August 22, 2026. - Agenda includes considering fundraising via preferential issue of equity shares/convertible securities to promoters and non-promoters. - Trading window closed from August 19, 2026, until 48 hours post-meeting.

- Audio recording of Sigachi Industries Limited's Q1 FY 2026-27 Earnings Call is available on the company's website (www.sigachi.com) as of August 13, 2026.

- Q1 FY27 Consolidated Operating Revenue ₹121.27 Cr vs ₹128.25 Cr (▼5.44% YoY) - EBITDA ₹16.51 Cr vs ₹24.10 Cr (▼31.48% YoY) - PAT ₹8.14 Cr vs ₹(100.97) Cr (Swung from loss to profit YoY) - EBITDA Margin 13.62% vs 18.79% (▼517 bps) - 3,50,57,990 convertible warrants lapsed, leading to a forfeiture of ₹22.87 Cr by the company.

- Q1 FY27 Consolidated Revenue ₹121.27 Cr vs ₹128.25 Cr (▼5.43% YoY) - EBITDA ₹16.51 Cr vs -₹96.90 Cr (swung to profit from loss YoY) - PAT ₹8.14 Cr vs -₹100.97 Cr (swung to profit from loss YoY) - EBITDA Margin 13.62% vs -75.56% (expanded by 8918 bps YoY) - The Board approved the lapse and forfeiture of 3,50,57,990 convertible warrants, resulting in a forfeiture of ₹228.75 Cr. - Re-appointment of Ms. Dhanalakshmi Guntaka and Mr. Janardhana Reddy Yeddula as Independent Directors for a second term of five years. - Re-appointment of Mr. Chidambarnathan as a director.

- Q1 FY27 Consolidated Operating Revenue ₹121.27Cr vs ₹128.25Cr (▼5.44% YoY) - EBITDA ₹16.51Cr vs ₹24.10Cr (▼31.49% YoY) - PAT ₹8.14Cr vs (Loss) ₹100.97Cr (▲108.06% YoY - turnaround from loss to profit) - EBITDA Margin 13.62% vs 18.79% (▼517bps) - Forfeiture of 3,50,57,990 convertible warrants, amounting to ₹22.88Cr, due to non-exercise of conversion option. - Board approved the re-appointment of Ms. Dhanalakshmi Guntaka and Mr. Janardhana Reddy Yeddula as Independent Directors for a second term of five years. - Mr. Chidambarnathan was re-appointed as a Director by rotation.

- Q1 FY27 Operational Revenue: ₹1,213 Mn - EBITDA: ₹165 Mn - PAT: ₹82 Mn - EBITDA Margin: 13.60% - PAT Margin: 6.76%

- Q1 FY27 Consolidated Revenue ₹121.27Cr vs ₹128.25Cr (▼5.44% YoY) - EBITDA ₹17.52Cr vs (₹92.96Cr Loss) (Shift from loss to profit YoY) - PAT ₹8.14Cr vs (₹100.97Cr Loss) (Shift from loss to profit YoY) - EBITDA Margin 14.44% vs -72.49% (Significant improvement YoY) - Board approved the re-appointment of Ms. Dhanalakshmi Guntaka and Mr. Janardhana Reddy Yeddula as Independent Directors for a second term of five years. - The Board approved the forfeiture of 3,50,57,990 convertible warrants (amounting to ₹22.87Cr) due to non-exercise of conversion option by holders. - Mr. Chidambarnathan was approved for re-appointment as he retires by rotation.

- Concall Schedule - Concall Date: Thursday, August 13, 2026 - Concall Time: 4:30 PM IST

- Board Meeting scheduled for August 13, 2026, to consider and approve Standalone and Consolidated unaudited financial results for the quarter ended June 30, 2026. - The trading window remains closed until 48 hours after the results announcement.

- Earnings Call for Q1 FY 2026-27 results, originally scheduled for Monday, July 27, 2026, at 4:30 PM, has been postponed. - The postponement is due to unavoidable circumstances. - The Company will inform the Stock Exchanges about the revised date in due course.

- Board Meeting scheduled for July 27, 2026, to approve Q1 FY27 financial results postponed. - Postponement is due to unavoidable circumstances. - Revised date will be intimated.

- Concall Schedule - Concall Date: July 27, 2026 - Concall Time: 4:30 PM IST

- Board meeting of Sigachi Industries Limited scheduled for July 27, 2026. - To consider and approve Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2026.

- Trading window closed for designated persons and their relatives from July 01, 2026, until 48 hours after Q1 FY27 financial results dissemination. - Board Meeting will be scheduled to approve unaudited financial results for the quarter ended June 30, 2026.